SOPHiA GENETICS SA SOPH 深 沪
已收盘 10-17 16:00:00 美东时间
4.31
-0.130
-2.93%
华盛通- 最 高4.429
- 今 开4.31
- 成交量 7.97万股
- 最 低 4.25
- 昨 收 4.44
- 总市值 2.91亿
- 52周最高 4.92
- 市盈率 静 --
- 换手率 0.12%
- 52周最低 2.58
- 委 比 67.32%
- 总股本 6757.96万
- 历史最高 19.80
- 量 比 0.56
- 振 幅 4.03%
- 历史最低 1.685
- 每 手 1
- 风险率 0.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SOPHiA GENETICS And A.D.A.M. Innovations Partner To Launch AI-Powered Liquid Biopsy Genomic Testing And Develop Companion Diagnostic For Cancer Care In Japan
- A.D.A.M. Innovations, Japan's leading private genetic testing company, and SOPHiA GENETICS (NASDAQ:SOPH), an AI technology company pioneering data-driven medicine, today announced at ESMO a strategic
10-16 23:02
Myriad Genetics And SOPHiA GENETICS Collaborate To Develop And Provide Pharmaceutical Companies With Innovative Global Liquid Biopsy Companion Diagnostic Test
Myriad Genetics (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (NASDAQ:SOPH), an AI technology company transforming precision medicine, announced a strategic
09-23 20:02
SOPHiA GENETICS SA: Positive Earnings Call Highlights
Sophia Genetics Sa (($SOPH)) has held its Q2 earnings call. Read on for the mai...
08-07 09:12
SOPHiA GENETICS Reports Financial Results for Mid-2025
SOPHiA GENETICS ( ($SOPH) ) just unveiled an announcement. On August 5, 2025, S...
08-05 18:54
Sophia Genetics Affirms FY2025 Sales Guidance of $72.000M-$76.000M vs $74.200M Est; Projects Adjusted EBITDA Loss Between $35M-$39M
Sophia Genetics (NASDAQ:SOPH) affirms FY2025 sales outlook from $72.000 million-$76.000 million to $72.000 million-$76.000 million vs $74.200 million estimate.
08-05 18:48
Sophia Genetics Q2 EPS $(0.33) Misses $(0.23) Estimate, Sales $18.323M Beat $17.480M Estimate
Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.23) by 43.48 percent. This is a 43.48 percent decrease over losses of $(0.23) per share from
08-05 18:46
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025
Soleno Therapeutics announced that two abstracts on VYKAT™ XR (diazoxide choline) for treating hyperphagia in Prader-Willi syndrome (PWS) patients will be presented at the Endocrine Society's 2025 Annual Meeting in San Francisco. The studies focus on glycemic outcomes over four years and peripheral edema over 4.5 years. VYKAT XR, approved by the FDA, is the first treatment for hyperphagia in PWS, with safety considerations including hyperglycemia...
07-01 12:00
SOPHiA GENETICS Releases 2024 ESG Impact Summary
SOPHiA GENETICS ( ($SOPH) ) has issued an announcement. On May 16, 2025, SOPHiA...
05-16 22:19
芯声：没法继续扩大芯片出口封锁范围，是美国不想吗？是做不到
随着中美关税战进入短暂缓和期，中美科技竞争可能会成为下一个关注热点。当地时间5月13日，美国商务部正式发布文件，启动撤销拜登任内签署的《AI扩散规则》，同时宣布...
05-15 14:51
